GENT logo

Gentian Diagnostics ASA Stock Price

OB:GENT Community·NOK 581.2m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

GENT Share Price Performance

NOK 37.60
-17.80 (-32.13%)
NOK 60.00
Fair Value
NOK 37.60
-17.80 (-32.13%)
37.3% undervalued intrinsic discount
NOK 60.00
Fair Value
Price NOK 37.60
AnalystConsensusTarget NOK 60.00

GENT Community Narratives

·
Fair Value NOK 60 37.3% undervalued intrinsic discount

Expanding Into $18 Billion Diagnostics Market Will Boost Prospects Despite Potential Risks

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

GENT logo

GENT: Pipeline Reallocation After Assay Exit Will Support Future Upside

Fair Value: NOK 60 37.3% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with high growth potential.

2 Risks
2 Rewards

Gentian Diagnostics ASA Key Details

NOK 182.1m

Revenue

NOK 81.0m

Cost of Revenue

NOK 101.1m

Gross Profit

NOK 109.5m

Other Expenses

-NOK 8.4m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 20, 2026
-0.54
55.51%
-4.62%
0%
View Full Analysis

About GENT

Founded
2001
Employees
64
CEO
Matti Heinonen
WebsiteView website
www.gentian.com

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.

Recent GENT News & Updates

Narrative Update Jun 22

GENT: Pipeline Reallocation After Assay Exit Will Support Future Upside

Analysts have maintained their fair value estimate for Gentian Diagnostics at NOK 60.0, citing largely unchanged assumptions on growth, margins and future P/E that support a steady price target outlook. What’s in the News for Gentian Diagnostics Gentian Diagnostics ASA has decided to discontinue development of its NT proBNP heart failure biomarker assay after a review of performance data and market conditions, citing limited commercial demand and high technical risk in a competitive market.
Narrative Update Jun 06

GENT: Pipeline Reallocation And Share Mandate Will Support Future Upside

Analysts have kept their fair value estimate for Gentian Diagnostics steady at NOK 60, with small tweaks to assumptions such as discount rate, long term revenue growth, profit margin and future P/E helping to fine tune the underlying valuation rather than shift the price target meaningfully. What's in the News Gentian Diagnostics has discontinued development of its NT proBNP heart failure biomarker after reviewing performance data and market conditions, concluding the assay is unlikely to meet required clinical decision cut offs without a long, high risk development extension.

Recent updates

No updates